Diltiazem versus adenosine for treating supraventricular tachycardia in the emergency room
PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department: PERVADE-ED Study
This study will see if IV diltiazem or IV adenosine works better and causes fewer side effects for adults who come to the emergency department with supraventricular tachycardia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT07086560 on ClinicalTrials.gov |
What this trial studies
This observational study compares adults presenting to the emergency department with acute SVT who receive IV adenosine, IV diltiazem, or both, collecting clinical outcomes and patient-reported side effects. Researchers will record treatment success, hemodynamic effects, adverse events, and patients' perceptions of symptom distress after medication. Enrollment is limited to English-speaking adults able to complete surveys and excludes pregnant or incarcerated patients and those too unstable to participate. All study activities occur at the University of Iowa Health Care emergency department.
Who should consider this trial
Good fit: Adults aged 18 or older who come to the ED with acute SVT and receive IV adenosine and/or IV diltiazem and who can complete surveys in English are ideal candidates.
Not a fit: People who are pregnant, incarcerated, non-English speaking, or too medically unstable to complete surveys would not be eligible and are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the results could help clinicians choose the medication that stops SVT effectively while causing less patient distress and fewer adverse events.
How similar studies have performed: Direct head-to-head comparisons of adenosine and diltiazem are limited, so this observational comparison addresses a relatively under-studied question rather than following a well-established precedent.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ED encounter for acute SVT 2. Age \>/= 18 years 3. Receipt of IV adenosine and/or IV diltiazem for SVT in the ED or prehospital setting Exclusion Criteria: 1. Neurologic status precluding survey participation due to medical instability 2. Pregnant 3. Incarcerated 4. Non-English speaking
Where this trial is running
Iowa City, Iowa
- University of Iowa Health Care — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Study coordinator: Anne Zepeski, PharmD
- Email: anne-zepeski@uiowa.edu
- Phone: 651-207-9357
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.